1. Home
  2. TSQ vs ENGN Comparison

TSQ vs ENGN Comparison

Compare TSQ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TSQ

Townsquare Media Inc.

HOLD

Current Price

$5.37

Market Cap

105.4M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.91

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSQ
ENGN
Founded
1996
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Broadcasting
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
105.4M
117.2M
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
TSQ
ENGN
Price
$5.37
$1.91
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$11.50
$21.08
AVG Volume (30 Days)
55.8K
667.0K
Earning Date
05-11-2026
06-11-2026
Dividend Yield
12.80%
N/A
EPS Growth
N/A
56.85
EPS
N/A
N/A
Revenue
$427,380,000.00
N/A
Revenue This Year
$2.22
N/A
Revenue Next Year
$0.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$1.40
52 Week High
$7.97
$12.25

Technical Indicators

Market Signals
Indicator
TSQ
ENGN
Relative Strength Index (RSI) 43.47 55.13
Support Level $5.34 $1.67
Resistance Level $5.52 $1.95
Average True Range (ATR) 0.22 0.07
MACD -0.01 0.01
Stochastic Oscillator 43.89 80.56

Price Performance

Historical Comparison
TSQ
ENGN

About TSQ Townsquare Media Inc.

Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: